The Festival of Genomics and Biodata, London 2026

The UK’s largest life sciences event is back! Celebrating its 11th year, the Festival has become the annual cornerstone for the UK life sciences community. With more speakers and sessions than ever, the 2026 edition promises to be the most impressive yet. Expanding beyond genomics, the Festival now encompasses a wide range of topics, including AI, biodata, cancer diagnostics, drug discovery, genomic medicine, proteomics, multi-omics, single-cell, spatial, and more.
28 January 2026
to 29 January 2026
ExCel, London
, London
, United Kingdom

Visit biomodal at booth 

#180

About the event


Genetics alone doesn’t tell the full story. Join us to explore the 6‑base genome—where 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) reveal a cell’s dynamic state and early signals of change, helping you predict the future. Visit booth to learn:

One Solution: How duet multiomics solution evoC delivers 6‑base data with unrivaled sensitivity and specificity in a single workflow

Why conventional sequencing methods aren’t enough: What standard approaches overlook in methylation state changes and gene regulation.

Early indicators of disease: How 5hmCand 5mC patterns illuminate activation and identity—and why that matters for detection.

Would you like to meet up in person? Book your onsite meeting with one of our biomodal attendees by filling out the form below. ⬇️

Presenting at the event

The 6-base genome provides synergistic biomarkers for earlier detection of colorectal cancer 

Dr. Sophie Kirschner

Associate Director, Translational Medicine, Early Oncology

AstraZeneca

Wednesday 28 January 2026 | Epigenetics Stage | 12:00 PM - 12:30 PM

Early detection of cancer can greatly improve treatment outcomes. This study explores the 6-base genome, A, C, G, T, 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) as biomarkers for early-stage colorectal cancer (CRC) in cell-free DNA (cfDNA) and matched tissue. We recapitulated a study performed by biomodal using whole genome sequencing to analyse untreated CRC patients and healthy controls, focusing on differentially methylated regions (DMRs) in stages I and IV. Combining 5mC and 5hmC measurements significantly improved diagnostic accuracy compared to traditional methods. We found increased 5hmC at stage I and decreased 5mC at stage IV, indicating that 5hmC can effectively track demethylation in tumour development. These findings suggest that distinguishing between 5mC and 5hmC enhances the sensitivity of liquid biopsy tests for early-stage cancer detection.

Find the venue

One sample. One workflow. One solution.

Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.

Related resources

Attending from biomodal

Donna McDade Walker

Donna McDade Walker, PhD

Vice President, Global Marketing & Product Management
Edi Canepa

Edi Canepa

Product Manager (Genomic Assays)
Ibrahim Cicek

Ibrahim Cicek

Field Application Scientist
Leonardo Motta

Leonardo Motta

Territory Account Manager – UK, Ireland & Nordics
Peter Fromen

Peter Fromen

Chief Executive Officer
Rob Osborne

Robert Osborne, PhD

Senior Vice President, Research & Development

Register now

Meet our team at the event

FOG London 2026 28-29JAN26
316246617308

Stay up to date

Explore recent biomodal news and the events that we’ll be attending in the near future.

What are you looking for?